https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-08 / Cancer Immunol. Immunother. 2010 Sep;59(9):1295-312
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-08 / Cancer Immunol. Immunother. 2010 Sep;59(9):1295-3122010-06-08 00:00:002019-02-15 08:50:10Anti-HER2 vaccines: new prospects for breast cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-01 / Expert Opin Biol Ther 2010 Jun;10(6):983-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-01 / Expert Opin Biol Ther 2010 Jun;10(6):983-912010-06-01 00:00:002019-02-15 08:48:35INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-01 / Expert Rev Respir Med 2010 Jun;4(3):311-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-01 / Expert Rev Respir Med 2010 Jun;4(3):311-42010-06-01 00:00:002010-06-01 00:00:00Dendritic cell vaccination as a treatment modality for mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-05-01 / J. Immunother. 2010 May;33(4):425-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-05-01 / J. Immunother. 2010 May;33(4):425-342010-05-01 00:00:002019-02-15 08:48:07Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-05-01 / Curr Opin Urol 2010 May;20(3):241-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-05-01 / Curr Opin Urol 2010 May;20(3):241-62010-05-01 00:00:002019-02-15 08:53:01Current status of immunological therapies for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-04-28 / J. Immunol. 2010 Jun;184(11):5954-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-04-28 / J. Immunol. 2010 Jun;184(11):5954-82010-04-28 00:00:002019-02-15 08:52:59Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-04-20 / Semin. Immunol. 2010 Jun;22(3):173-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-04-20 / Semin. Immunol. 2010 Jun;22(3):173-822010-04-20 00:00:002019-02-15 08:40:20Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-04-07 / J. Biomed. Biotechnol. 2010;2010:752381
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-04-07 / J. Biomed. Biotechnol. 2010;2010:7523812010-04-07 00:00:002019-02-15 08:40:21Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-04-01 / Expert Rev Neurother 2010 Apr;10(4):483-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-04-01 / Expert Rev Neurother 2010 Apr;10(4):483-62010-04-01 00:00:002019-02-15 08:46:44Dendritic cell vaccines to combat glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-252010-04-01 00:00:002021-11-15 14:45:11Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours
